MyFinsight
Home
Blog
About
Contact
Download
Download image
Purchases of short-term
investments
-$933,840K
Purchases of property,
plant and equipment
-$8,389K
Acquisition of licenses and
other assets, net
-$2,789K
Net cash provided by
investing activities
$395,091K
Drug development
-$247,281K
Canceled cashflow
$549,927K
Selling, general and
administrative
-$102,689K
Drug discovery
-$57,099K
Other segment items
-$56,943K
R&d support
-$41,821K
Manufacturing and development
chemistry
-$31,308K
Medical affairs
-$12,353K
Cost of sales
-$4,261K
Net increase
(decrease) in cash and cash...
-$295,143K
Canceled cashflow
$395,091K
Other current and
long-term assets
-$116,099K
Net loss
$59,465K
Deferred contract
revenue
$29,783K
Non-cash royalty revenue
related to sale of...
-$26,789K
Accounts payable
$26,021K
Inventories
-$14,938K
Amortization of discount on
investments, net
-$11,873K
Non-cash losses related
to other assets
$3,683K
Income taxes
$94K
Canceled cashflow
$494,290K
Principal payments on
mortgage debt
-$79K
Proceeds from sale of
short-term investments
-$549,927K
Net cash used in
operating activities
-$661,945K
Canceled cashflow
$288,745K
Net cash provided by
financing activities
-$27,406K
Effects of exchange
rates on cash
-$883K
Canceled cashflow
$79K
Revenue
-$494,290K
Escrow deposit for
maturity of 0 percent...
$632,511K
Contracts receivable
$75,205K
Accrued compensation
-$67,592K
Accrued liabilities and
other liabilities
-$66,680K
Stock-based compensation
expense
-$47,279K
Non-cash interest
related to sale of future...
-$37,780K
Loss (gain) on
investments, net
$13,146K
Depreciation
-$3,448K
Amortization of right-of-use
operating lease assets
-$3,318K
Amortization of debt issuance
costs
-$2,591K
Amortization of other assets
-$1,140K
Proceeds from issuance of
common stock through...
-$27,485K
Back
Back
Cash Flow
IONIS PHARMACEUTICALS INC (IONS)
IONIS PHARMACEUTICALS INC (IONS)
source: myfinsight.com